NEWARK, Calif., Nov. 28, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that Martin McGlynn, President and CEO, will present a business update at the 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum to be held November 30-December 1 at the Sanford Consortium for Regenerative Medicine Building, La Jolla, California. Mr. McGlynn is scheduled to speak on Wednesday, November 30, at 10:48 am PST.
The Company's presentation will be videotaped by the Alliance for Regenerative Medicine (ARM) and will be available beginning on Friday, December 2 through the Company's corporate website at http://www.stemcellsinc.com/News-Events/Events.htm under the Events section. The video will remain accessible through the Company's website for 30 days following the event. The video will also be accessible directly at http://events.fullviewmedia.com/meeting-on-the-messa/.
The Stem Cell Meeting on the Mesa's Investor and Partnering Forum is being organized by the Sanford Consortium, the California Institute for Regenerative Medicine (CIRM) and the Alliance for Regenerative Medicine to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one meetings. More information is available at the event website at www.stemcellmeetingonthemesa.com.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. In addition, the Company plans to file an IND by year-end 2011 to initiate a clinical trial of HuCNS-SC cells in the dry form of age-related macular degeneration, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven®brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.
The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the timing and prospects associated with filing an IND to initiate a clinical trial in age-related macular degeneration; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and in its subsequent reports on Forms 10-Q and 8-K.